Evidence map›Paper›PMID 30460327›Full record

ArticleOncoscience2018

ETV4: an emerging target in pancreatic cancer.

Sachin Kumar Deshmukh, Ajay P Singh, Seema Singh

Abstract read
In one paragraph

Article in Oncoscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sachin Kumar DeshmukhMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA.
Ajay P SinghMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA.
Seema SinghMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA.

Funding

Targeting tumor-stromal interaction for pancreatic cancer therapyR01CA175772 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.9M
A novel molecular cross-talk driving pancreatic cancer progressionR01CA224306 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2018 to 2022
$1.7M
ETV4 in pancreatic cancerR03CA169829 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, SEEMA · 2012 to 2013
$144k
NCI NIH HHS R01 CA175772NCI NIH HHS R01 CA224306NCI NIH HHS R03 CA169829
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cyclin D1ETV4pancreatic cancer

Identifiers

PMID30460327
PMCPMC6231443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.